Abingworth LLP Verona Pharma PLC Transaction History
Abingworth LLP
- $301 Million
- Q4 2022
A detailed history of Abingworth LLP transactions in Verona Pharma PLC stock. As of the latest transaction made, Abingworth LLP holds 2,457,500 shares of VRNA stock, worth $228 Million. This represents 21.3% of its overall portfolio holdings.
Number of Shares
2,457,500
Previous 2,457,500
-0.0%
Holding current value
$228 Million
Previous $25.1 Million
155.92%
% of portfolio
21.3%
Previous 8.58%
Shares
3 transactions
Others Institutions Holding VRNA
# of Institutions
291Shares Held
74.3MCall Options Held
933KPut Options Held
1.98M-
Perceptive Advisors LLC New York, NY6.56MShares$609 Million17.44% of portfolio
-
Janus Henderson Group PLC London, X05.52MShares$512 Million0.2% of portfolio
-
Darwin Global Management, Ltd. St. Helier, Y93.92MShares$364 Million17.31% of portfolio
-
Frazier Life Sciences Management, L.P. Menlo Park, CA3.46MShares$321 Million13.82% of portfolio
-
Eventide Asset Management, LLC Boston, MA2.89MShares$268 Million3.9% of portfolio
About Verona Pharma plc
- Ticker VRNA
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 60,954,200
- Market Cap $5.66B
- Description
- Verona Pharma plc, a clinical stage biopharmaceutical company, focuses on development and commercialization of therapies for the treatment of respiratory diseases with unmet medical needs. The company's product candidate is ensifentrine, an inhaled and dual inhibitor of the phosphodiesterase (PDE) 3 and PDE4 enzymes that acts as both a bronchodi...